## A Michiga Corporation Center For Cholesterol Management

FAR HAD AAbedi

11/02/196/

DATE 6/14/10

Farhad cornes in today on follow up. He is dring well and has no 40.

Presence of 3 or more collegion define Melaponic Syndrome;

Walst > 10 ME ASIAN

2 Habe carbonald (MF)

176 > 100 market

4 FBS > 100 mg/d= 0. DM

5 BP > 130 /305 (or an moderate)

1000:0' e = e = - £

LDL-Pr 1278 on 3/18/10.

Clestor 20 mg 9 d Zetia long 9 d trilipux 135mg 2d 02FA Ygpaws 9d

PHYSICAL EXAM

RR W 109/7-P 70

GENERAL WOWN O'M NAP

CHEST Clan

HEART MARIE

EXTREMNTIES WALL

16 1R. Mixed hymelynden

De ONME alle and of

A Michigan Comporation Center for Cholesterol Management

Farhad NAME AMBA AAbedi

208 11 02 1961

(Presence of 3 or more criterion define Metabolic Syndrome)

2 HDL-C < 40'50mg dL .M F1'

3 TG > 150 mg/di.

4 FBS > 100 mg/dL or DM

5 BP > 130 >85' for on medication:

Lipopio' e Besuis

LAL-Pr 1147 on 1/5/09

MEDS

Mestor zomaggd trilipix 135mg2d Zetia 10mg 9d Baby Aspirin OBFA 4000mg 2d

PHYSICAL EXAM

BP 110170 . P 72 RA 16 T98

GENERAL WOWNO in MAP

CHEST Class

ABDOMEN - Soft, NT, Sp Choleystecting EXTREMITIES WALL

48 go Persiand E 1/0 MH: Met. Symule

ONMA Dwell call o losed

# Center for Cholesterol Management

NAME FAHID AABED

DATE 11/16/00

DOB . 11/02/1961

HISTORY OF PRESENT ILLNESS

Farhad comes on % 2 day 1/0
antenis, chest pain & movement;

PMHX Delp inspyration, also I when he
lay them. Had, 60-61

Metabolic Syngrome Criterion (Presence of 3 or more criterion define Metabolic Syndrome)

- 1. Waist > 40"/35" (M/F) Waist > 35"/32" (M/F Asian)
- 2. HDL-C < 40/50mg/dL (M/F)\*
- 3. TG > 150 mg/dL\*
- 4. FBS > 100 mg/dL or DM
- 5. BP > 130 / >85\* (\* or on medication)

Lipoprofile Results

**MEDS** 

Crestor 20mg 2d Trilipix 135mg 2d Zetia lomg 2d Baby Aspirin 03 Fish Oil 4 ag 2d

NAME

PHYSICAL EXAM

BR 16

GENERAL WDWN Du MAN

Clean CHEST

HEART

ABDOMEN SHIP WITTES

EXTREMITIES

WWW.

Assessment 4850 leman or = MH, Met Symptom c Mn-landiae chest pa

A Medical Corporation

## Center for Cholesterol Management

NAME AAbed: FARHAD DOB 11/02/1961

DATE

HISTORY OF PRESENT ILLNESS

Metabolic Syndrome Oriterion (Presence of 3 or more criterion define Metabolic Syndrome)

- 1. Waist > 40"/35" (M/F) Waist > 35"/32" (M/F Asian)
- 2. HDL-C < 40/50mg/dL (M/F)\*
- 3. TG > 150 mg/dL\*
- 4. FBS > 100 mg/dL or DM
- 5. BP > 130 / >85\* (\* or on medication)

Lipoprofile Results

LM-Pr 1286 m 7/5/00

O crestor 20 mg Pogd

O tribitix 135 mg 80 gd

O 20 Ha 10 mg Pogd

O 3FH 4 9mg Pogd

O ABY AS pirin.

PHYSICAL EXAM

GENERAL WOWN OF ON MAN

CHEST // //

ABDOMEN

EXTREMITIES WANT

Assessmen: 47 y Mallair 67 T Met. Gymdenne; MH

De Mar meds

Builliallians

# Center for Cholesterol Management

DOB 11/02/1961

DATE 1/7/2009

Forhad unus in today for follow up.
He is down very well and has no %

Owntined hymelenica

Metabolic Syndrome Oriterion
Presence of 3 or more criterion define Metabolic Syndrome)

- 1. Waist > 40".35" (M·F) Waist > 35" 32" (M/F Asian)
- 2.  $HDL-C < 40.50 mg/dL (M/F)^{*}$
- 3 TG > 150 mg/dL\*
- 4. FBS > 100 mg.dL or DM
- 5. BP >130 ->85\* (\* or on medication)

poprof e Resulis

Maun 7/7/09

Cresta 20 mg po gol Tillyte 135 mg po gol 63 FA 45mg po gol Baly ASA gol

PHYSIOAL EX<u>am</u>

3=111/08 == 72 == 16

GENERAL WOUNDOWNAM

OMEST Clean


MAR

ABBOMEN Syff, MT EXTREMITIES Warm


4750 Sumian o'è met syndems ;

Ount meds

Din Bullalli results



ME AABIdi FANhae		CHART NUMBER
4/21/09 Partent de For HIS AP	duot sh	owed up
- HV 1715 M 17		ma
		APR 2 7 2003
B/P-124/68	A 75	NML + CHS
Furhal and a	i to the	to difficulto
He Stephen	03FA	CERPSI MILLEL
Just motalis	aco so	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Montal	Mount	malenia
16- WAN 130 mM	AN	
124/10 75	<u>/</u>	
test-den		
11-1000		
1- 50/A 1/1		
2/0 4750 Manua	in of Ein	et indeene
(i) Caret as		
(5) M/M/		
(a) 110 / (m)	IT Must	



FEB 2 5 2009

NAME: Forhad HAABedi	CHART NUMBER:
ON = 115/72 0-80	
Fuchal ames a todas	In humatile
Hollow and We dust	issed tilled
Manazonent aus	Myselva and
anniched his guest	
PMHZ	
Mulestein	
Mulesters Chance Sund	
Manuelle - 500 Alle	11/2/2/
Mamma - De Will	10/10/10/10/10
PE- WPWW of an NAM	)
1151 0011	
772	
Mest-close	
m Man	
	, , ,
11/1/ - 6/1/ ///	······································
	······································
Walm - Walm.	
9/10//augus	Met. Statistellen
Mulelland	alla land
wollecto Mille of C	1/11/and
19/11/4/4/11/10 (13F)	41 - 1/
S Mate In In 11	1 / Jal
000000000000000000000000000000000000000	101 rayua
(3) Bul HSA 10 19	135mach
3	
4) 7/48 Who	
<i>y</i>	

## THE CENTER FOR CHOLEST OL A Medical Corporation 1950 Sawtelle Blvd, Suite 150 NAME: FAR had AAbedi **MANAGEMENT**

FEB 1 2 2009

CHIEF COMPLAINT;
CHIEF COMPLAINT: -  47 20 Draman & E 1/1 Molester  HISTORY OF PRESENT ILLNESS: Mesents for NMR  April testing.
HISTORY OF PRESENT ILLNESS: MESEULS JUMP
A denies their pain a 50 B
OMI devad
had strestert 2 years ago -> uf
Has no neducial his pt took crest a south south of the stopped it
and soft and floi to took ourta
PMHX: De la Stopped of
O Molester Mino reason
Dehmu simusites

PSHX: O Septoplant

MEDS: Baly ASA of

ALLERGIES: MKDA

SOCIAL HISTORY:

Stobacco

FAMILY HISTORY:

**REVIEW OF SYSTEMS:** 

PHYSICAL EXAM

BP=125/80 P= 76 RR /6 T

**GENERAL:** 

WDWNJJuNA

HEENT:

**NECK:** 

CHEST:

**HEART:** 

**ABDOMEN:** 

**BACK:** 

**EXTREMITIES:** 

**NEURO:** 

LABORATORIES:

PROBLEMS: 4750 Draman of the

ONME OF/Week Mas

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 5,343,389; 6,518,069; 6,576,471; 6,653,140; and 7,243,030. CLIA: 34D0952253

NMR LipoProfile® test

1. Reference population comprises 5,382 men and women not on tipid medication enrolled

in the Multi-Ethnic Study of Atherosclerosis (MESA). More, et al. Atherosclerosis 2007.

IPOSCIENCE LIPOSCIENCE

Wed 16 Jun 2010 11:02:39 AM EDT


Page 14 of 18
LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27616
877-547-6837
www.liposcience.com

Clinician Page 1 of 1 Sex Age Patient Name RICHMAN, MICHAEL AABEDI, FARHARD M 48 Client Name and Address 15057/ Center for Cholesterol Mgmt 1950 Sawtelle Blvd Accession Number Birth Date Patient ID Suite 150 T0669822 11/02/1961 16240583 Los Angeles, CA 90025 Fax: (310)481-3949 Phone: (310)481-3939 Fasting Status Requisition Number Report Date and Time Date Received Date Collected **FASTING** 16240583 06/15/2010 23:18 06/15/2010 06/14/2010

Reference Range

LDL-P (LDL Particle Number)	, , <del>, _</del> -	20th Low Mode < 1000 1000-	rate Borderline-High	95th High 1600-2000	Very High > 2000
LDL-C (calculated)	mg/dL 88	Near or opting opting 100-	na! Borderline-Hig	h High 160-189	Very High ≥190
HDL-C	mg/dL 46 Desirable ≥ 40	<b>Triglycerides</b>	mg/dL 103 Tot esirable < 150	tai Cholestero	mg/dL 155 Desirable < 200
Historical Rep	orting	· · · · · · · · · · · · · · · · · · ·		Mung	3 402-1
LDL-P	600 700 800 900 16				40mg/
LDL-C	40 60 70 BO				Much Color
Servity State		▶06/14/10 (88)			


The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 5,343,389; 6,518,069; 6,576,471; 6,653,140; and 7,243,030. CLIA: 34D0952253



Page 15 of 18 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

Clinician Page 1 of 1 Sex Age RICHMAN, MICHAEL Patient Name М 48 AABEDI, FARHARD Client Name and Address 15057/ Center for Cholesterol Mgmt Accession Number Birth Date 1950 Sawtelle Blvd Patient ID Suite 150 T0669822 11/02/1961 16240583 Los Angeles, CA 90025 Fax: (310)481-3949 Phone: (310)481-3939 Fasting Status Requisition Number Report Date and Time Date Received Date Collected FASTING 16240583 06/15/2010 23:18 06/15/2010 06/14/2010

### PARTICLE CONCENTRATION AND SIZE



These laboratory assays, validated by LipoScience, have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values has not been fully established.

<sup>1.</sup> Garvey WT, et al. Diabetes. 2003; 532:463-462. 2. Goff DC et al. Metabatism 2006; 54:284-270. 3. LipoScience reference population comprises 4,688 men and women without known CVD or diabetes and not on lipid medication.



2500 Sumner Blvd. • Raleigh, NC 27616 (919) 21/-1999 • FAX (919) 212-1954 CLIA #34D0952253



16240583

	•1			1024056	1 <u>.1</u>	
FACILITY		PATIENT IN	FOR <sub>E</sub>	ecion All infoi for sain	mation must be compliple to be processed	leted
Center for Cholesterol Mgmt 1950 Sawtelle Blvd Suite 150 Los Angeles, CA 90025 (310)481-3939 Fax: 1310481	5057 3949	Social Security Number  Last Name  Address		Patient ID/Medica	al Record Number  Middle	
Designate Requesting Clinician  13 1972554806 RICHMAN, MICHAE	i F	Date of Birth (mm/dd/y Telephone	(- <u> </u>	State  Male  Female	Zip  Y Fasting  Non-Fastin	g
		INSURANCE	: REQ		copy of insurance card and back)	
			]Insura	nce Clie	nt Pati	ient
		Medicare No. (including BCBS ID No. (including BCBS)				
		Insurance Company Nac	ne			
		Insured Name  Member/Insured ID#		Employe Group #	er Name/Employer #	<b>-</b>
		Claims Address				
Additional Clinician: NPI:	<u></u>	City Patient Relation to Insur	red:	State Self Spouse	Zip  Dependent	
Collection Date (mm/dd/yy)  Collection Time  ICD-9 Code(s): REQUIRED		Patient/Responsible Part LipoScience for services as descripted responsibility for payment of charge Patient/Responsible Part	bed herein and ges for laborat	l authorize payment directly to itsory services that are not covere	LipoScience. I agree to assume	/ <u>/</u>
8 [] 6060 620\110\125\140\150\1	79\245\4		., Olymatai			
PANELS (See back for list of tests included in each panel)	INDIVIDUA	L TESTS		160 Insulin (CPT	83525)	5
NMR LipoProfile® test (LDL-P only)  Chamical Lipida L Partials Consentration & Size	140 ALT (C	PT 84460)	P/S	195 LDL Choles	terol, Direct (CPT 83721	) P/S
Chemical upids+Particle Concentration & Size	<del></del>	PT 84450)	P/S		(CPT 83704)	P/S
NMR LipoProfile® test (LDL-P only) Chemical Lipids+Particle Concentration & Size P/S +Homocysteine+CRP		terol, Total (CPT 82465)	S P/S	100 Lp(a) (CPT 8	rofile® test	P/S
620 MMR LipoProfile® test (LDL-P, HDL-C, TG by NMR) TC+Particle Concentration & Size		ne Kinase (CK), Total (CPT 8			C, TG by NMR) (CPT 83704	4)
·		igh Sensitivity (CPT 86141) se (CPT 82947)	P/S OX	602* Particle Con 410 TSH (CPT 84	centration & Size (CPT &	33704) P/S
630 MMR LipoProfile® test (LDL-P only) LDL-P+Particle Concentration & Size		emoglobin (A1c) (CPT 830	<del></del> -	420 T-4, Free (0	<u> </u>	
S99 Lipid Panel, Chemical Method P/S (CPT 80061)	190 HDL C	holesterol (CPT 83718) cysteine (CPT 83090)	P/S P/S	430 T-4, Total (	<del></del>	5
Label Placement : Does Not Sl		* These Drug Adr (see back provided	laboratory-d ninistration. k for list of t in a laborat	eveloped assays have not Whether requested individests included in each pane ory report separate from the separate from	been cleared by the US For Jually (602) or as part of a I), the results of these ass hat provided for other test	a test panei says will be ts.
16240 <b>58</b> 3 ( 16240	583		White/Caud Black/Afric Other:	an American	Hispa  Asian  Decli	,

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 5,343,389; 6,518,069; 6,576,471; 6,653,140; and 7,243,030. CLIA: 34D0952253

Mon 22 Mar 2010 09:11:31 AM EST

LIPOSCIENCE

Page 4 of 11 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com


Clinician Page 1 of 1 Sex Age Patient Name RICHMAN, MICHAEL M AABEDI, FARNAD 48 Client Name and Address 15057/ Center for Cholesterol Mgmt Accession Number 1950 Sawtelle Blvd Birth Date Patient ID Suite 150 F0628812 11/02/1961 16154152 Los Angeles, CA 90025 Fax: (310)481-3949 Phone: (310)481-3939 Fasting Status Requisition Number Report Date and Time Date Received Date Collected NON-FASTING 16154152 03/20/2010 04:56 03/19/2010 03/18/2010 NMR LipoProfile® test Reference Range 95th 80th Percentile<sup>1</sup> 50th 20th Very High High Borderline-High Moderate nmol/L Low > 2000 1600-2000 1300-1599 1000-1299 < 1000 LDL-P 1278 (LDL Particle Number) Near or above Lipids Very High Borderline-High High optimal Optimal mg/dL ≥190 160-189 130-159 100-129 < 100 88 LDL-C (calculated) mg/dL mg/dL mg/dL Total Cholesterol 158 Triglycerides 142 HDL-C 42 Desirable < 200 Desirable < 150 Desirable ≥ 40 LDL-C is inaccurate if patient is non-fasting. Historical Reporting 600 700 800 900 1000 1100 1206 (808 3406 4606 3566 1700 1800 1900 2000 4000 6000 LDL-P **▶**03/18/10 (1278) 100 200 400 (P. 190 200 400 P. 190 200 400 LDL-C

1. Reference population comprises 5,382 men and women not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. *Atherosclerosis* 2007.

**▶**03/18/10 **(88)** 

© 2009 LipoScience, Inc. All rights received

The NMR LipoProfile ® test may be covered by one or more issued. or pending patents, including U.S. Patent Nos. 5,343,389; 6,516,069; 6,576,471; 6,653,140; and 7,243,030. CLIA: 34D0952253




Page 5 of 11 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

Page 1 of 1

Clinician Sex Age Patient Name RICHMAN, MICHAEL Μ AABEDI, FARNAD 48 Client Name and Address 15057/ Center for Cholesterol Mgmt Birth Date Accession Number 1950 Sawtelle Blvd Patient ID Suite 150 F0628812 11/02/1961 16154152 Los Angeles, CA 90025 Fax: (310)481-3949 Phone: (310)481-3939 Fasting Status Requisition Number Report Date and Time Date Received Date Collected NON-FASTING 16154152 03/20/2010 04:56 03/18/2010 03/19/2010

### PARTICLE CONCENTRATION AND SIZE



These laboratory assays, validated by LipoScience, have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values has not been fully established.

2500 Sumner Blvd. • Raleigh, NC 27616 (919) 2<sup>1</sup>3-1999 • FAX (919) 212-1954 CLIA #34D0952253



· · · · · · · · · · · · · · · · · · ·				1.6	3154117		
FACILITY		PATIENT IN	NFORMA	NOI	Ail intermeti for sample f	on mast hercomp o be price soul	wied
Jenter For Cholesterol Mgmt 1950 Sawtelle Blvd Juite 160 OS Angeles, CA 90026 (310)481-3939 Fax: 1310481		Social Security Number  Last Name  Address  City  Date of Birth (mm/do	1 (00)	rst Name	<u> </u>	Cord Number  Middle  Zip  Fasting  Non-Fastir	ng
		INSURANC	E : REQU	IRED	Artach coay Juant and b	ar ansaronco con Reck i	d
		Medicare	Insuranc	e	Client	Pal	tient
		Medicare No. (Incl		<u> </u>			]
		BCBS ID No. (incl	uding prefix)				
		Insurance Company	Name		<del>.</del>	·	
		Insured Name			Employer Na	ame/Employer #	
		Member/Insured ID#	New		Group #	··	<del></del>
		Claims Address	4		, (	<u>,, -</u>	<del></del>
		Clty		11/11	State	Zip	
Additional Clinician: NPI:	× <u> </u>	Patient Relation to In	sured: 🔯 S	ielf [		Dependent	
Collection Date (mm/dd/yy) Collection Time		Patient/Responsible i	Party Signature:	I hereby auti	norize the release of	medical information to	ne
ICD-9 Code(s): REQUIRED		responsibility for payment of	charges for laboratory	services that	are not covered by	the healthcare insurer.	,
			$\sim n(1)$	£		2/19/1	m
372.0		Patient/Responsible I		· · · · · · · · · · · · · · · · · · ·		Date	
E 3 6060 SZGN110N125N140N150N1  ANELS (See back for list of tests included in each panel)	79\245\4	: 			Insulin (CPT 835		
NMR LipoProfile® test (LDL-P only) Chemical Lipids+Particle Concentration & Size		(CPT 84460)	P/S P/S		LDL-P Only (CP	ol, Direct (CPT 837) T 83704)	21)
MMR LipoProfile® test (LDL-P only)		(CPT 84450) ptide (CPT 84681)	5 S		Lp(a) (CPT 8369		
LO Chemical Lipids+Particle Concentration & Size P/S +Homocysteine+CRP	180 Chok	esteroi, Total (CPT 82465 tine Kinase (CK), Total (C	<del></del>	545 🗌	NMR LipoProfile (LDL-P, HDL-C, T	e <sup>e</sup> test G by NMR) (CPT 837	704)
20 MRR LipoProfile® test (LDL-P, HDL-C, TG by NMR) TC+Particle Concentration & Size		High Sensitivity (CPT 86		602*	Particle Concer	ntration & Size (CP	т <b>83704</b>
NMR LipoProfile® test (LDL-P only) P/S		ose (CPT 82947)	ОХ		TSH (CPT 84443		<del> </del>
LDL-P+Particle Concentration & Size		chemoglobin (A1c) (CPT			T-4, Free (CPT T-4, Total (CPT		
99 Lipid Panel, Chemical Method P/S (CPT 80061)		Cholesterol (CPT 83718) nocysteine (CPT 83090)	P/S		Triglycerides (	·	
		* Ti Dru (sec	nese laboratory-deving Administration. We back for list of test vided in a laborator OPTIONAL White/Cauca Black/African	hether req ts included y report se sian	uested individual in each panel), t parate from that	n cleared by the US ly (602) or as part of the results of these a provided for other to	assays tests.
1615-152 / 1515-	P & 13 m.	<u></u>	Other:		- Const limas		~!

collection, Storage, and Shipping Instructions on Back

ATTACH ABN IF NECESSARY

White Copy - LipoScience Yellow Copy - Client

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 8,578,471 CLIA:34D0952253



Wed 18 Nov 2009 04:00:47 PM EST

Page 2 of 3 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

Page 1 Clinician Sex Age Patient Name RICHMAN, MICHAEL М 48 AABEDI, FARHAD Client Name and Address 15057/ Center for Cholesterol Mgmt Accession Number 1950 Sawtelle Blvd Suite 150 Birth Date Patient ID Los Angeles, CA 90025 T0542993 11/02/1961 16007398 Phone: (310)481-3939 FAX: (310)481-3949 Fasting Status Requisition Number Report Date and Time Date Received Date Collected FASTING 16007398 11/18/2009 04:21 11/17/2009 11/17/2009 LDL PARTICLE NUMBERS Near or above Very High High Borderline-high optimal Optimal nmol/L >2000 1600-2000 1300-1599 1000-1299 <1000 1147 LDL-P (LDL Particle Number) High Borderline-high Moderate Low nmol/L >1200 850-1200 600-849 884 <600 Small LDL-P Moderately High-Risk Patients High-Risk Patients -primary goal: LDL-P<1300 nmol/L -primary goal: LDL-P<1000 nmol/L PATIENT -secondary goal: small LDL-P<850 nmol/L -secondary goal: small LDL-P<850 nmol/L **GOALS** Near or above LIPIDS Very High High Borderline-high optimal **Optimal** mg/dL >=190 160-189 130-159 100-129 <100 60 LDL-C (calculated) mg/dL mg/dL mg/dL **Total Cholesterol** 142 **Triglycerides** 178 HDL-C 46 Desirable <200 Desirable <150 Desirable >=40

	nm	Large (Pattern A)		Small (Pattern B)
LDL Particle Size	20.0	23.0 - 20.6		20.5 - 18.0
	μmol/L	Low Risk	Intermediate	High Risk
Large HDL-P	1.2	>9.0	4.0 - 9.0	<4.0
	nmol/L	Low Risk	Intermediate	High Risk
Large VLDL-P	2.1	<0.5	0.5 - 5.0	>5.0

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,576,471 CLIA:34D0952253

Page 2




Page 3 of 3

LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

 Patient Name
 Accession Number
 Requisition Number
 Report Date and Time

 AABEDI,FARHAD
 T0542993
 16007398
 11/18/2009 04:21



Lipoprotein subclass particle numbers are given in parentheses above each bar. The height of the bar is the percentile indicating if the value is "high" or "low" based on a reference population consisting of >6,900 subjects enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA).

## COMMENTS Amended Report

#### PRACTITIONER'S NOTES

1) New optimal 201-10 2) Cont meds 3) 1 03FA 9) 7/4 3 months

© 2005 LipoScience, Inc. All Rights Reserved

\*\* Final Page \*\*



2500 Sumner Blvd. • Raleigh, NC 27616 (919 12-1999 • FAX: (919) 212-1954

CLIA #34D0952253



398

FACILITY			
Center for Cholestero	l Mgii	nt 1	E057
1950 Sawtelle Blvd	_		
Suite 150			
Los Angeles, CA 90025			
(310)481-3939 Fax	: 131	0481	3949
Designate Requesting Clinician			

EU 1973557294	- UYEDA: KUI	BERT Y	
			Telephone IF PATIENT IS NONFASTING CHECK HERE
			Insurance (REQUIRED) Attach copy
			☐ Medicare ☐ Insurance ☐ Client
			Medicare Number (including suffix)
			BCBS ID Number (including prefix)
			Insurance Company Name
			Insured Name
			Member/insured ID#
			Claims Address
Additional Clinician:		NPI	City
Collection Date	Collection Tim	ie 4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	Patient Relation to Insured Self Spo
mm dd	уу	· · · · · · · · · · · · · · · · · · ·	Signature: I hereby authorize the releas

All information must be completed to sample to be processed Patient\_ID/Medical Record Number Social Security Number Middle First Name Last Name **Address** Contract 16 City Female f insurance card droat& back) ☐ Patient . . . . . . . . . mployer Name/Employer# Group# Dependent L\_\_Spouse L\_\_ Patient Relation to Insured L\_ISelf Party Signature: I hereby authorize the release of medical information to LipoScience for services as described herein and authorize payment directly to LipoScience. I agree to assume responsibility for payment of charges for laboratory services that are not covered by the healthcare insurer.

1040 Dr Richman's Initial Panel

ICD-9 Code(s) (MANDATORY)

S	The second of		D or S	100 Lp(a)	P or S
		180 Cholesterol, Total	P or S		
3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4,	P or S	245 Creatine Kinase (CK), Total	P or S	410 TSH	
220 NMR LipoProfile® (includes CPT codes 83704 + 80061)	1 0. 5	125 CRP-High Sensitivity	P or S	420 T-4, Free	
	P or S		OX	430 T-4, Total	
375	I UI S	179 Glycohemoglobin (A1c)	L	185 Triglycerides	Pors
540 Lipoprotein Quantification by NMR with TC	P or S		P or S	COLLEGIZATION	
(includes CPT codes 83704 + 82465)	1 01 0	110 Homocysteine	P or S	P = 4 ml Plasma, Lavender Top  S = 4 ml Serum, Red Top Tube or C	reiner gel tubes*
		160 Insulin	S	* No other gel tubes are accep	otable
140 ALT	P or S	195 LDL Cholesterol, Direct Method	P or S	P or S = Plasma or Serum Accep	
	P or S	210 Lipid Panel, Chemical Method	P or S	L = Whole Blood, Lavender Top	
.50 AST	S	301 Lipoprotein Quantification by NMR	P or S	OX = Whole Blood, Gray Top (oxal	ate/fluoride) Tube
70 C-Peptide	o see the	CMS policy for specific limits regarding the fr	equency	of lipid testing.	лите

Patient/Responsible Party Signature



16007398



16007398



16007398



16007398

Produced under patent Ilcenses to U.S. Patent Nos. 4,933,844, 5,343,389, 8,518,089, and 8,578,471 CLIA:34D0952253

Wed 07 Oct 2009 10:45:56 AM EDT

Page 2 of 6
LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27616
877-547-6837
www.liposcience.com

Clinician

NMR LIPEPROFILE

P	а	a	e	1
	•	_		ı

Patient	Name	26X	Age	RICHMAI	N,MICHAEL			
AABEDI,FARHAD	)	M	47		Client Nam	e and Add	lress	
Patient ID 15984801	Birth Date 11/02/1961	Accession N	<del></del> :	1950 Sav Los Ange Phone: (3	r Cholesterol Mo vtelle Blvd Suite eles, CA 90025 310)481-3939 0)481-3949			<b>50</b> 57/
Date Collected D	Date Received	Repor	rt Date and	_ <del></del>	Requisition N	umber	Fas	ting Status
	10/06/2009	10/0	07/2009 0	8:36	159848	301	NON-	-FASTING
LDL-P (LDL Particle Number	1311	Optir <10	паІ	ar or above optimal	Borderline-high	High 1600-20		Very High >2000
	nmol/L		.ow	Modera	ate Borde	rline-high	<b>I</b>	High
Small LDL-P	1106	<del> </del>	300	600-8	49 850	)-1200 ***********************************	<b>!</b>	>1200
Small LDL-P  PATIENT GOALS		atients	amol/L	A	Aoderately High orimary goal: LDL- secondary goal: sn	- <b>Risk Pal</b> P<1300 nm	101/L	
PATIENT	High-Risk Pa -primary goal: I -secondary goa	atients	amol/L P<850 nmol/ Ne	A	noderately High	- <b>Risk Pal</b> P<1300 nm	101/L <850 nm	
PATIENT GOALS LIPIDS LDL-C	High-Risk Paragraphic primary goal: Language secondary goal: Language mg/dL 66	atients LDL-P<1000 r al: small LDL-l	amol/L P<850 nmol/ Ne mal	ar or above	orimary goal: LDL-secondary goal: sr	P<1300 nn	101/L <850 nm	ol/L
PATIENT GOALS	High-Risk Paragraphic primary goal: Language secondary goal: Language mg/dL 66	atients LDL-P<1000 r al: small LDL-l	amol/L P<850 nmol/ Ne mal	ar or above optimal	Borderline-high 130-159	P<1300 nm	101/L 2850 nm	ol/L Very High >=190 mg/dL 132
PATIENT GOALS  LIPIDS  LDL-C (calculated)	### High-Risk Parimary goal: It secondary goal: It	atients LDL-P<1000 r al: small LDL-l  Option  Trigly	mol/L P<850 nmol/ Ne mal 00 ycerides	ar or above optimal  100-129  mg/dL  138  Desirable <1	Borderline-high 130-159 Tota	P<1300 nm nall LDL-Pa High 160-18	sterol	Very High >=190  mg/dL  132  Desirable <20
PATIENT GOALS  LIPIOS  LDL-C (calculated HDL-C	High-Risk Parimary goal: Lang/dL secondary goal mg/dL 66 mg/dL 38 Desirable >=40 if patient is nonfast	atients LDL-P<1000 r al: small LDL-l  Cptin  <10  Trigly  ting.	nmol/L P<850 nmol/ Ne mal 00 ycerides	ar or above optimal  100-129  mg/dL  138  Desirable <1	Borderline-high 130-159	P<1300 nm nall LDL-Pa High 160-18	sterol	Very High >=190  mg/dL  132  Desirable <20
PATIENT GOALS  LIPIDS  LDL-C (calculated)  HDL-C	High-Risk Parimary goal: Lang/dL secondary goal mg/dL 66 mg/dL 38 Desirable >=40 if patient is nonfast	atients LDL-P<1000 r al: small LDL-l  Cptin  <10  Trigly  ting.	nmol/L P<850 nmol/ Ne mal 00 ycerides	ar or above optimal  100-129  mg/dL  138  Desirable <1	Borderline-high 130-159 Tota	P<1300 nm nall LDL-P High 160-18 Ioping Type Sm	sterol	Very High >=190  mg/dL  132 Desirable <29  s Mellitus.  ern B)
PATIENT GOALS  LIPIDS  LDL-C (calculated)  HDL-C	High-Risk Parimary goal: In-secondary goal: In-seco	atients LDL-P<1000 r al: small LDL-l  Cptin  <10  Trigly  ting.	mol/L P<850 nmol/ Ne mal oo ycerides	ar or above optimal 100-129  mg/dL 138  Desirable <1	Borderline-high 130-159 Tota	P<1300 nm nall LDL-P  High  160-18  Joping Type  Sm	sterol 20.5 - 18	Very High >=190  mg/dL  132  Desirable <20  s Mellitus.  ern B)
PATIENT GOALS  LIPIDS  LDL-C (calculated) HDL-C  LDL-C is inaccurate  METABOLIC S	High-Risk Parimary goal: In-secondary goal: In-seco	atients LDL-P<1000 r al: small LDL-l  Optim  <10  ARKERS	mol/L P<850 nmol/ Ne mal 00 ycerides These	ar or above optimal 100-129  mg/dL 138  Desirable <1	Borderline-high 130-159 Tota	P<1300 nm nall LDL-P  High  160-18  Joping Type  Sm	sterol 20.5 - 1/2	Very High >=190  mg/dL  132  Desirable <20  s Mellitus.  ern B)

Low Risk

<0.5

Large VLDL-P

nmol/L

2.8

Small LDL

Size

(≤20.5 nm)

High Risk

>5.0

High Large VLDL-P (>5.0 nmol/L)

Intermediate

0.5 - 5.0

Low Large HDL-P (<4.0 µmol/L)

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,576,471 CLIA:34D0952253



Wed 07 Oct 2009 10:45:56 AM EDT


Page 3 of 6

LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

Page 2

 Patient Name
 Accession Number
 Requisition Number
 Report Date and Time

 AABEDI,FARHAD
 T0517261
 15984801
 10/07/2009 08:36



Lipoprotein subclass particle numbers are given in parentheses above each bar. The height of the bar is the percentile indicating if the value is "high" or "low" based on a reference population consisting of >6,900 subjects enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA).

PRACTITIONER'S NOTES

| LILL-P= |31|
| T6-|38

| Muce hyper chalesterilesses
| Ount Meds
|

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,578,471 CLIA:34D0952253

Wed 07 Oct 2009 10:45:56 AM EDT



Page 4 of 6 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

### Page 3

Sex Age Patient Name 47 М AABEDI, FARHAD Accession Number Birth Date Patient ID T0517261 11/02/1961 15984801

Clinician	<u> </u>
RICHMAN,MICHAEL	
Client Name and Add	ress
Center for Cholesterol Mgmt 1950 Sawtelle Blvd Suite 150 Los Angeles, CA 90025 Phone: (310)481-3939 FAX: (310)481-3949	15057/

Date Collected	Date Received	Report Date and Time	Requisition Number	Fasting Status
10/05/2009	10/06/2009	10/07/2009 08:36	15984801	NON-FASTING

Test	Patient's Results		Reference Range	Units
	Within Range	Outside Range		
ALT	24		10-60	IU/L
AST	19		10-42	IU/L





34801

	All information must be completed for sample to be processed
FACILITY	
Center for Cholosterol Mont 15057	
1950 Savtelle Blvd	Social Security Number Patient ID/Medical Record Number
Suite 150	HH Beat FORFORD
Los Angeles, CA 90025 (B10)481-B9B9	Last Name   Middle   Middle
	Address (10077)
Designate Requesting Clinician	City  Date of Birth  11 1 2 1 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
13 1972554806 RICHMAN: MICHAEL F 13 1073557294 UYEDA: ROBERT Y	Date of Birth (mm/dd/yy)
	Telephone IF PATIENT IS NONFASTING CHECK HERE
	Insurance (REQUIRED) Attach copy of insurance card most & bards
	☐ Medicare ☐ Insurance ☐ Client ☐ Patient
	Medicare Number (including suffix)
	BCBS ID Number (including prefix)
	Insurance Company Name  FORMACIA APPOINT
	Insured Name (CTYX 270 A 5 / 98 /   Employer Name/Employer#
	Member/Insured ID# BOX 60007. Group#
	Claims, Address 105 Anyllis 1A 90060
Additional Clinician: NPI	City State Zip
Collection Date / D / D / Collection Time 1-10 pur	Patient Relation to Insured Self Spouse Dependent
ICD-9 Code(s) (MANDATORY)	LipoScience for services as described herein and authorize payment directly to LipoScience. I agree to assume responsibility for payment of charges for laboratory services that are not covered by the healthcare incurse.
1/4.4	Patient/Responsible Party Signature  Date
[] 1040 Dr Richman's Initial Panel	

	1.00 A 1.00 A 2000 CONTRACTOR CON					
_/		E ju aan	180 Cholesterol, Total	P or S	100 Lp(a)	P or !
20 🗹	NMR LipoProfile®	P or S	245 Creatine Kinase (CK), Total	P or S		
	(includes CPT codes 83704 + 80061)		125 CRP-High Sensitivity	P or S	420 T-4, Free	
75	NMR LipoProfile®+Homocysteine+CRP	P or S	178 Glucose	OX	430 T-4, Total	
	(includes CPT codes 83704 + 80061 + 83090 + 86141)		179 Glycohemoglobin (A1c)	L	185 Triglycerides	P or S
	ipoprotein Quantification by NMR with TC	P or S	190 HDL Cholesterol	P or S	COFFICATION	
(1	includes CPT codes 83704 + 82465)		110 Homocysteine	P or S	P = 4 ml Plasma, Lavender Top Tube	
			160 Insulin	S	S = 4 ml Serum, Red Top Tube or Greiner gel tub	es*
ю	ALT	P or S	195 LDL Cholesterol, Direct Method	P or S	* No other gel tubes are acceptable	
50 T	AST		· · · · · · · · · · · · · · · · · · ·		P or S = Plasma or Serum Acceptable	···- <u>·</u>
		P or S		P or S	L = Whole Blood, Lavender Top Tube	
<u>ю 🗌 _</u>	C-Peptide A	S	301 Lipoprotein Quantification by NMR	P or S	OX = Whole Blood, Gray Top (oxalate/fluoride) T	ube
	Please	see the	CMS policy for enecific limits regarding the fre	MILER ON A	flinid tacting	

policy for specific limits regarding the frequency of lipid testing.



15984801



15984801



15984801



15984801

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,576,471 CLIA:34D0952253



Page 4 of 10

LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27816 877-547-6837 www.liposcience.com

Page 1

Page I	iant Nama		۸		Clinician	
	ient Name	Sex	Age	RICHM	AN,MICHAEL	
AABEDI,FARH	AD	⊢ M	47		Client Name and Add	ress
Patient ID	Birth Date	Accession N	lumber		for Cholesterol Mgmt awtelle Blvd Suite 150	15057/
15914222	11/02/1961	W0463	598	Los Angeles, CA 90025 Phone: (310)481-3939 FAX: (310)481-3949		
Data Oallastad	Daka Dakabasa	D	1 D-1	· · · · · · · · · · · · · · · · · · ·	<del></del>	
Date Collected	Date Received	Hepor	t Date and	ı ime	Requisition Number	Fasting Status
07/07/2009	07/08/2009	07/0	9/2009	19:14	15914222	FASTING
	<u> </u>	<del></del>				

LDL PARTICLE	NUMBERS					
<b>LDL-P</b> (LDL Particle Number)	nmol/L 1286	Optimal <1000	Near or above optimal 1000-1299	Borderline-high 1300-1599	High 1600-2000	Very High >2000
Small LDL-P	nmol/L 1036	Low <600	Modera 600-84	<b>1</b>	rline-high 0-1200	High >1200
PATIENT GOALS	High-Risk Patiers -primary goal: LDL-i	P<1000 nmol/L	- <b>p</b>	foderately High primary goal: LDL- secondary goal: sr	P<1300 nmol/L	
LIPIDS	mg/dL	Optimal	Near or above optimal	Borderline-high	High	Very High
LDL-C (calculated)	82	<100	100-129	130-159	160-189	>=190
HDL-C	mg/dL <b>40</b> Desirable >=40	Triglyceride	mg/dL S 153 Desirable < 15		al Cholester	mg/dL  153  Desirable <200
METABOLIC SYNDROME MARKERS These markers increase the risk of developing Type 2 Diabetes Mellitus.						
	nm	Large (Pat	tern A)	•	Small (Pa	ittern B)
LDL Particle Size	20.1	23.0 - 2	20.6		20.5 -	
Large HDL-P	μmol/L <b>3.3</b>	Low Risk >9.0		Intermediate 4.0 - 9.0	H	igh Risk <4.0
Large VLDL-P	nmol/L_ 2.1	Low Risk <0.5		Intermediate 0.5 - 5.0		ligh Risk >5.0
	Small LDL Size (≤20.5 nm)		Low Large HDL (<4.0 µmol/	-P	High Large VLC (>5.0 nmo	DL-P
	District Description					** Continue *


Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,369, 8,518,089, and 6,576,471 CLIA:34D0952253



Page 5 of 10
LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27616
877-547-6837
www.liposcience.com

Page 2

Patient Name	Accession Number	Requisition Number	Report Date and Time
AABEDI,FARHAD	W0463598	15914222	07/09/2009 19:14



PRACTITIONER'S NOTES

IMPrined hyperlysellen ILMI-In 1256

OMMANDEN SOME GOT

© 2005 LipoScience, Inc. All Rights Reserved

\*\* Final Page \*\*




2500 Sur ner Blvd. • Raleigh, NC 27616 (919) 2 1999 • FAX: (919) 212-1954

CLIA #34D0952253



15914222



		180 [Cholesterol, Total Por S		Lp(a)	P 0F S
NMR LipoProfile®	P or S	<sup>245</sup> Creatine Kinase (CK), Total	P or S	410 TSH	S
(includes CPT codes 83704 + 80061)		125 CRP-High Sensitivity	P or S	420 T-4, Free	S
NMR LipoProfile®+Homocysteine+CRP	P or S	178 Glucose	OX	430 T-4, Total	S
(includes CPT codes 83704 + 80061 + 83090 + 86141)		179 Glycohemoglobin (A1c)	L	185 Triglycerides	P or S
10 Lipoprotein Quantification by NMR with TC	P or S	190 HDL Cholesterol	P or S		
(includes CPT codes 83704 + 82465)		110 Homocysteine	P or S		
		160 Insulin	S	S = 4 ml Serum, Red Top Tube or •  * No other gel tubes are acce	_
ю ALT	P or S	195 LDL Cholesterol, Direct Method	P or S		<u> </u>
		<del>_</del>		1 UI 5 - I lasilla UI SCI ulli Acce	<u>-                                      </u>
50 AST	P or S	210 Lipid Panel, Chemical Method	P or S	L = Whole Blood, Lavender To	p Tube
<sup>70</sup> C-Peptide	S	301 Lipoprotein Quantification by NMR	P or S		late/fluoride) Tube
Please	e see the	CMS policy for specific limits regarding the fre	equency (	of lipid testing.	




15914222



15914222



14222



15914222

### Valley Internal Medicine Admin 5805 Sepulveda Blvd Ph- 818-908-8048

Patient: Aabedi, Farhad DOB: 11/02/1961 Tel: 310-389-7989

Lab: -CBC				
Order Date	06/09/2009			
Name/Collection Date	06/09/2009			
WBC	5.0(4.1-10.9 K/UL)			
RBC	5.28(4.20-6.30 M/UL)			
HEMOGLOBIN	15.8:12.0-18.0 G/DL)			
HEMATOCRIT	45.3(37.0-51.0 %)			
MCV	85.7(80.0-97.0 FL)			
MCH	29.5(26.0-32.0 产 <b>G</b> )			
MCHC	34,5(31.0-36.0 G/OL)			
RDW	12.9(11.5-15.0 %)			
PLATELETS	253(140-440 K/UL)			
MPV	9 8(7.3-12.5 FL)			
NE#	3.1(2.2-4.8)			
NE# LYMPH#	1.4(0.6-4.1 K/UL)			
MONO#	0.4(0.3-0.8 K/bl)			
EO#	0.1(C.0-0.2)			
BASQ#	0.0(0.0-0.1 ]			
NE%	83.1(43.0-86.0 %)			
LYMPH%	27.4(10.0-58.5 %)			
MONO%	7.1(5.5.11.7 %)			
EO%	2.3(0.9-2.9 %)			
BASO%	0.2(0.2-1.0 %)			

Lab: -COMPREHEN METABOLIC PANEL				
Order Date	06/09/2009			
Name/Collection Date	06/09/2009			
GLUCOSE	84(79-115 MG/DL)			
UREA NITROGEN	15(8-26 MG/DL)			
CREATININE	0.7(0.6-1.3 MG/DL)			
BUN/CREAT RATIO	21(10-24 RATIO)			
CALCIUM	9.7(8.6-10 C MG/DL)			
AST (SGOT)	26(15-41 IU/L)			
ALKALINE PHOSPHATASE	40(38-126 IU/L)			
TOTAL BILIRUBIN	2.8 H (0.3-1.2 MG/DL)			
TOTAL PROTEIN	7.6(6.5-8.1 G/DL)			
ALBUMIN	4.8(3.2-5.5 G/DL)			
A/G RATIO	1.5(1.0-2.7 RATIO)			
SODIUM	135(138-144 MMOL/L)			
POTASSIUM	3.713.6-5.1 MMCL/L)			
CHLORIDE	104(101-111 MMOL/L)			
eGFR (NON-AFRICAN AMERICAN)	128(>80 m L/min :			
eder (African American)	155(>60 mL/min)			

Lab: -CRP (ULTRA SENSITIVE)					
Order Date	06/09/2009				
Name\Collection Date	06/09/2009				
ULTRA SENSITIVE CRP	0.59(<7.48 MG/L)				

Lab: -HEMOGLOBIN A1C

Order Date	06/09/2009			
Name\Collection Date	06/09/2009			
%HBA1C	5.4(4.6-6.2 %)			

Lab: -LIPID PANEL				
Order Date	06/09/2009			
Name\Collection Date	06/09/2009			
CHOLESTEROL	141(<200 MG/DL)			
TRIGLYCERIDES	200 H (35-160 MG/DL)			
DIRECTHOL	38(<60 MG/DL)			
LDL	62(60-13C MG/DL)			
VLDL	40.0(6.0-40.0 MG/DŁ)			
CHOLESTEROL/HDL	4(2-5 RATIO)			

Lab: -PSA					
Order Date	06/09/2009				
Name\Collection Date	06/09/2009				
PSA-Hybritech	0 4(0 C-4 D NG/ML)				

Lab: -THYROID PANEL (general)					
Order Date	06/09/2009				
Name\Collection Date	06/09/2009				
TSH	1.06(0.34-5.60 u!U/ML)				
TOTAL T4	11.0(5.0-12.0 UG/DL)				
T-UPTAKE	39.2(32.0-48.4 %)				
FREE THYROXINE INDEX	11(5-12 INDEX)				

Lab: -URINALYSIS COMPLETE				
Order Date	06/09/2009			
Name\Collection Date	06/09/2009			
COLOR	YELLOW()			
CLARITY	CLEAR()			
6년	7.0()			
SPECIFIC GRAVITY	1.015( )			
PROTEIN	NEGAT(VEL)			
urine glucose	NEGATIVE()			
URINE KETONE	NEGATIVE( )			
BILIRUBIN	NEGATIVE()			
URINE BLOOD	NEGATIVE: /			
NITRITE	NEGATIVE: )			
UROBIL!NOGEN	0.2 £.U./dÇ( )			
LEUKOCYTES	NEGATIVE( )			
URINE RBC	NONE()			
MBC	NONE()			
BACTERIA	TRACE A ( )			
MUCUS	NEGATIVE( )			
CRYSTALS	NEGATIVE()			
CASTS	NEGATIVE()			
SQ. EPITHELIAL CELLS	NEGATIVE()			

Patient: Asbedi, Farhad DOB: 11/02/1961

ADMINISTRAÇÃO DE CONTRAÇÃO DE LA COMPLETA DE CONTRAÇÃO DE

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,369, 6,518,069, and 6,576,471 CLIA:34D0952253



Wed 29 Apr 2009 02:15:44 PM EDT

Page 5 of 7 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

Page 1

Clinician Patient Name Sex Age RICHMAN, MICHAEL AABEDI, FARHAD M 47 Client Name and Address Center for Cholesterol Mgmt 15057/ Patient ID Birth Date Accession Number 1950 Sawtelle Blvd Suite 150 Los Angeles, CA 90025 15824791 11/02/1961 T0437750 Phone: (310)481-3939 FAX: (310)481-3949 Date Collected Date Received Report Date and Time Requisition Number Fasting Status

04/27/2009	04/28/2009	04/29/2009 13:19	1582	NON-FASTING
· · · · · · · · · · · · · · · · · · ·		·	· · · · · · · · · · · · · · · · · · ·	
LDL PARTICI	ENUMBERS			
	nmol/L	Near or a Optimal optim		High Very High
LDL-P	983	<1000 1000-1		1600-2000 >2000
(LDL Particle Numb	per)			· [
	nmol/L		Moderate Bord	lerline-high High
Small LDL-P	838	<u> </u>	600-849 85	>1200
	High-Risk Patie	ents	Moderately Hig	h-Rick Dationte
PATIENT	-primary goal: LD	L-P<1000 nmol/L	-primary goal: LDL	
GOALS	-secondary goal:	small LDL-P<850 nmol/L	-secondary goal: s	mall LDL-P<850 nmol/L
UPIDS		Nearora	bove	
	mg/dL	Optimal optim	al Borderline-high	High Very High
LDL-C (calculate		<100 100-1	29 130-159	160-189 >=190
6 6 Pm. 5	mg/dL		ig/dL	mg/dL
HDL-C		Triglycerides		al Cholesterol 107
LDL-C is inecourate	Desirable >=40 If patient is nonfasting		ble <150	Desirable <200
CDC-O is maccurate	- patient is nomasting	·	· · · · · · · · · · · · · · · · · · ·	···· <del>-</del> ···-
METABOLICS	SYNDROME MAI	*KE用等 These marker	s increase the risk of deve	loping Type 2 Diabetes Mellitus.
	ПП	Large (Pattern A)		Small (Pattern B)
LDL Particle Size	20.0	23.0 - 20.6		20.5 - 18.0
	μmol/L	Low Risk	Intermediate	High Risk
Large HDL-P	1.9	>9.0	4.0 - 9.0	<4.0
	nmol/L	Low Risk	Intermediate	High Risk
Large VLDL-P	0.7	<0.5	0.5 - 5.0	>5.0
	Small LDL	Lo	W	High
	Size	Large I	HDL-P	Large VLDL-P
	( ≤20.5 nm)	(<4.0 μ	moi/L)	(>5.0 nmol/L)

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,089, and 6,575,471 CLIA:34D0952253



Wed 29 Apr 2009 02:15:44 PM EDT

Page 6 of 7
LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27818
877-547-8837
www.liposcience.com

Page 2

Patient Name Accession Number

Requisition Number


Report Date and Time

AABEDI, FARHAD

T0437750

15824791

04/29/2009 13:19



Lipoprotein subclass particle numbers are given in parentheses above each bar. The height of the bar is the percentile indicating if the value is "high" or "low" based on a reference population consisting of >6,900 subjects enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA).

#### PRACTITIONER'S NOTES

rtimal .
Impurful
- unt meds
- 4/2 3 mmte

© 2005 LipoScience, Inc. All Rights Reserved

\*\* Continue \*\*

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,578,471 CLIA:34D0952253



Wed 29 Apr 2009 02:15:44 PM EDT

Page 7 of 7
LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27816
877-547-8837
www.liposcience.com

Page 3

Patient Name Sex Age

AABEDI,FARHAD M 47

 Patient ID
 Birth Date
 Accession Number

 15824791
 11/02/1961
 T0437750

Clinician

Client Name and Address

Center for Cholesterol Mgmt 15057/
1950 Sawtelle Blvd Suite 150
Los Angeles, CA 90025
Phone: (310)481-3939
FAX: (310)481-3949

Date Collected	Date Received	Report Date and Time	Requisition Number	Fasting Status	
04/27/2009	04/28/2009	04/29/2009 13:19	15824791	NON-FASTING	

Test	Patient'	s Results	Reference Range	Units	
	Within Range	Outside Hange			
ALT	23		10-60	IU/L	
AST	20		10-42	IU/L	



2500 Sumner Blvd. • Raleigh, NC 27616 (91/~12-1999 • FAX: (919) 212-1954



#### CLIA #34D0952253 5824791 All information must be completed for sample to be processed FACILITY Center for Cholesterol Mgmt 1505 Patient ID/Medical Record Number Social Socurity Number 1950 Sawtelle Blvd Suite 150 Last Name Middle Los Angeles: CA 90025 (310)491-3939 fax: 131048:394 Address Designate Requesting Clinician City State Zip Female (mm/dd/yy) 1972554806 RECHMAN, MICHAEL F 1073557294 UYEDA, ROBERT Y Telephone IF PATIENT IS NONFASTING CHECK HERE Insurance (REQUIRED) Attach copy of insurance card (tont & back) Insurance Medicare ☐ Client ☐ Patient Medicare Number (including suffix) BCBS ID Number (including prefix) Insurance Company Name A BEL Insured Name Employer Name/Employer# Member/Insured ID# Claims Address Additional Clinician; City State

EJ 1040 Dr Richman's Initial Pane

Collection Time \_

ICD-9 Code(s) (MANDATORY)

·				· · · · · · · · · · · · · · · · · · ·	
		180 Cholesterol, Total	P or S	100 Lp(a)	P oi
NMR LipoProfile®	P or S	<sup>245</sup> Creatine Kinase (CK), Total	P or S		
(includes CPT codes 83704 + 80061)		125 CRP-High Sensitivity	P or S	420 T-4, Free	
NMR LipoProfile®+Homocysteine+CRP	P or S	178 Glucose	OX	430 T-4, Total	
(includes CPT codes 83704 + 80061 + 83090 + 86141)		179 Glycohemoglobin (A1c)	L	185 Triglycerides	P or
<sup>40</sup> Lipoprotein Quantification by NMR with TC	P or S	1∞ HDL Cholesterol	P or S		
(includes CPT codes 83704 + 82465)		110 Homocysteine	P or S	P = 4 ml Plasma, Lavender Top Tube	
NDVIII I		160 Insulin	S	S = 4 ml Serum, Red Top Tube or Greiner gel	tubes*
40 ALT	P or S	195 LDL Cholesterol, Direct Method	P or S	* No other gel tubes are acceptable  P or S = Plasma or Serum Acceptable	·
90 AST	P or S	210 Lipid Panel, Chemical Method	P or S	L = Whole Blood, Lavender Top Tube	
C-Peptide	S	301 Lipoprotein Quantification by NMR	P or S	OX = Whole Blood, Gray Top (oxalate/fluorid	le) Tube

Patient Relation to Insured

Patient/Responsible Party Signature

Please see the CMS policy for specific limits regarding the frequency of lipid testing.



**Collection Date** 

15824791



15824791



15824791



Spouse

Signature: I hereby authorize the release of medical information to

LipoScience for services as described herein and authorize payment directly to LipoScience. I agree to assume

responsibility for payment of charges for laboratory services that are not covered by the healthcare insurer,

\_\_Dependent

Date

15824791

#### From LipoScience

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,576,471 CLIA:34D0952253



Fri 13 Feb 2009 08:02:06 PM EST

Page 2 of 7 LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 877-547-6837 www.liposcience.com

Page 1

Sex Clinician Patient Name Age RICHMAN, MICHAEL AABEDI, FARHAD Μ 47 Client Name and Address Center for Cholesterol Mgmt 15057/ Patient ID Birth Date Accession Number 1950 Sawtelle Blvd Suite 150 Los Angeles, CA 90025 15744742 11/02/1961 F0416255 Phone: (310)481-3939 FAX: (310)481-3949 Date Collected Date Received Report Date and Time Requisition Number Fasting Status 02/12/2009 02/13/2009 02/13/2009 20:17 **FASTING** 15744742

				307 1 17 1L	INDITIO
LDL PARTICI	ENUMBERS	······································	<del></del>	· · · · · · · · · · · · · · · · · · ·	······································
	ten dere K. M. Medf. F. H. J. Ferdf. Facer H. T. Medf.	Neard	r above		
	nmol/L			rline-high High	h Very High
LDL-P	2502	<1000 1000	-1299 130	0-1599 1600-2	2000 >2000
(LDL Particle Numb	•				
0	nmol/L	Low	Moderate	Borderline-high	
Small LDL-P	2233	<600	600-849	850-1200	>1200
TI-1-	High-Risk Patie		Modera	itely High-Risk Pa	itients
PATIENT GOALS	-primary goal: LD -secondary goal:	L-P<1000 nmol/L smail LDL-P<850 nmol/L		goal: LDL-P<1300 n	
	goondary goan.	SITIALI CLICATI COSO TITIONE	-seconge	ary goal: small LDL-P	′<850 nmoi/£
LIPIDS		Near o	r above		
	mg/dL	Optimal opti	mal Borde	rline-high High	Very High
LDL-C (calculate	L	<100 100	-129 13	0-159 160-1	89 >=190
(02.03.20	mg/dL		mg/dL		mg/dL
HDL-C	39	Triglycerides	348	Total Chole	<del>,</del>
	Desirable >=40	Des	rable <150		Desirable <200
METARMICS	SYNDROME MAI	These mark	ers increase the r	isk of developing Type	2 Diabetos Mollitus
THE STATE OF STATE STATE OF	m i i m ffet m ffet men	TAN House house		ion or developing Type	Z DIADOIGS MIGHINGS.
	<u>г</u>	Large (Pattern A)		Sn	nall (Pattern B)
LDL Particle Size	19.3	23.0 - 20.6		#	20.5 - 18.0
	μmol/L	Low Risk	Interm	ediate	High Risk
Large HDL-P	3.7	>9.0		- 9.0	<4.0
	<u></u>		·	<del></del>	***************************************
	nmol/L	Low Risk		ediate	High Risk
Large VLDL-P	10.1	<0.5	0.5	- 5.0	>5.0
	Small LDL		_OW	,	High
	Size	Large	HDL-P 📗	Large	VLDL-P / nmol/L)
	(≤20.5 nm)	(<4.0	μmol/L)	(>5.0	nmol/L)

#### From LipoScience

Produced under patent licenses to U.S. Patent Nos. 4,933,844, 5,343,389, 6,518,069, and 6,576,471 CLIA:34D0952253




Page 3 of 7
LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27616
877-547-6837
www.liposcience.com


Page 2

Patient Name Accession Number Requisition Number Report Date and Time

AABEDI,FARHAD F0416255 15744742 02/13/2009 20:17



Lipoprotein subclass particle numbers are given in parentheses above each bar. The height of the bar is the percentile indicating if the value is "high" or "low" based on a reference population consisting of >6,900 subjects enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA).






2500 Sumner Blvd. • Raleigh, NC 27616 ) 212-1999 • FAX: (919) 212-1954 CLIA #34D0952253



15744742

V' company description of the second of the	All information must be completed for sample to be processed
FACILITY	
Contactors! Ng. 15057	
1980 Sawtelle Blvd Suitte 186 - 2	Social Security Number Patient ID/Medical Record Number Farnad
La Compeles CA 90025	Last Name   Middle
(.40)481-B9B9 Fax: 13.00030949	27/1 CUSIANO re.
	Address (A) CA 90077
Designate Requesting Clinician  Color 17 20 4806 RECHMAN MICHAEL F	City // State Zip
C. 1072004906 RICHMAN, MICHMEL F E 107200EE7294 UVEDA, NOBORO V	Date of Birth // / / / / / / (mm/dd/yy) Male Female
And the same of th	Telephone
	IF PATIENT IS NONFASTING CHECK HERE
	Insurance (REQUIRED) Attach copy of insurance card from & backs
	☐ Medicare ☐ Insurance ☐ Client ☐ Patient
	Medicare Number (including suffix)
	BCBS ID Number (including prefix)
	Insurance Company Name Furnad AABecli
	Insured Name  # Employer Name/Employer#
	6 Y X 290 A 5 198 7400 M 100.  Member/Insured ID# 6 Group#
	PO BOX 60007.
	Claims Address  (M 90060)
Additional Clinician: NPI	City State Zip
Collection Date $\frac{\sqrt{\frac{1}{2}}}{mm} \frac{\sqrt{\frac{1}{2}}}{dd} \frac{\sqrt{\frac{1}{2}}}{yy}$ Collection Time $\frac{\sqrt{\frac{1}{2}}}{\sqrt{\frac{1}{2}}} \frac{\sqrt{\frac{1}{2}}}{\sqrt{\frac{1}{2}}}$	Patient Relation to Insured Self Spouse Dependent
ICD-9 Code(s) (MANDATORY)	LipoScience for services as described herein and authorize payment directly to LipoScience. I agree to assume
	responsibility for payment of charges for laboratory services that are not covered by the healthcare insurer.
272.4	A TOTAL TOTA
	Patient/Responsible Party Signature Date
It togo br Richman's Initial Panel	

		* " # "	180 Cholesterol, Total	P or S	100 Lp(a)	P or
220	NMR LipoProfile®	P or S	<sup>245</sup> Creatine Kinase (CK), Total	P or S		
_	(includes CPT codes 83704 + 80061)		125 CRP-High Sensitivity	P or S	420 T-4, Free	
75	NMR LipoProfile®+Homocysteine+CRP	P or S	178 Glucose	OX	430 T-4, Total	
	(includes CPT codes 83704 + 80061 + 83090 + 86141)		179 Glycohemoglobin (A1c)	L	185 Triglycerides	Por
	Lipoprotein Quantification by NMR with TC	P or S	190 HDL Cholesterol	P or S		
	(includes CPT codes 83704 + 82465)		110 Homocysteine	P or S	P = 4 ml Plasma, Lavender Top Tube	·
			160 Insulin	S	S = 4 ml Serum, Red Top Tube or Greiner gel tub	bes*
40	ALT	P or S	195 LDL Cholesterol, Direct Method	P or S	* No other gel tubes are acceptable  Por S = Plasma or Server Assertable	
50	AST	P or S	210 Lipid Panel, Chemical Method	P or S	P or S = Plasma or Serum Acceptable  L = Whole Blood, Lavender Top Tube	
70	C-Peptide	S	301 Lipoprotein Quantification by NMR	P or S	OX = Whole Blood, Gray Top (oxalate/fluoride)	Tube
21000	Please	see the	CMS policy for specific limits regarding the fre	equency o	of lipid testing.	









15740760

Shipping Instructions on Back



## THE CENTER FOR CHOLESTEROL MANAGEMENT

A Medical Corporation 1950 Sawtelle Blvd, Suite 150 Los Angeles, CA 90025

\*\*\*\*Please complete all pages of this form\*\*\*

NAME: FARHAC	AABED	I	DATE: 12/12/
SEX:MF DO	B: 11/02/61	SSN: <u>56</u>	0517861 DL#: N900 282
ADDRESS: 2-11/	ASIANO R	り	
CITY: LA	S	TATE:	ZIP: 90077
FAX:	EMAI	L: fred a	a bed. Chot PHONE: 626-278-2
EMERGENCY CONTA	CT: Sher	1 Aabo	ZIP: 90077 Cabedi Chot PHONE: 626-278-2  PHONE: 626-278-4  PHONE:
ADDRESS:	/		
		TATE:	ZIP:
EMPLOYER:			THE TAX IN CO.
ADDRESS.	C	ITY:	STATE: ZIP:
Have you ever been diag	nosed with?		
High Blood Pressure	☐ Yes	∠ No	How long ago?
Diabetes	□ Yes	☑ No	How long ago?
Stroke	☐ Yes	□No	When did it occur?
High Cholesterol	Yes	□ No	What medications do you take for this, $before$
any? Nom - To	suk crestor	<u>5 mg</u>	bet to the total t
Lung Disease	□ Yes	$\square$ No	What type?

Heart Disease	∐ Yes	Z No			
Other Vascular Disease	☐ Yes	No			
List other medical proble taken medications or been					
Are you allergic to any m List those medications?	edications?	☐ Yes	No		
Are you allergic to X-Ray	y dye?	□ Yes	No		
List all surgeries, both m	ajor and min	or, you have l	ıad:		
SURGERY		DATE		HOSPITAL	
32ptuplusty		2007		baster Chi	n, e
			· · · · · · · · · · · · · · · · · · ·		
Have you ever smoked?	□ Yes	□No	How many	cigarettes per day?	· <del>,</del>
How long (have) did you	smoke (d)? _				<del>,</del> , <del></del>
If you quit, when did you	ı quit?	<u></u>	·	<u></u>	,
How many glasses per w	eek do you co	nsume of? W	INE	BEERCOCK	TAILS_\_
Has anyone in your fami	ly had any of	the following	illnesses?		
	WHICH	FAMILY ME	MBER	HOW OLD W	ERE THEY
Cancer	· - · · · · · · · · · · · · · · · · · ·	<u> </u>			<u></u>
Heart Attack	<u></u>		<u> </u>	,	<u> </u>
Angina or clogged arteri	ies				
Sudden death					
Hypertension			<u> </u>		<del> </del>
Other heart disease			····		······································

¥

igh cholesterol	
roke	
iabetes	
re you having or have you ever had? (check all for which t	the answer is "yes").
☐ Increasing Breathlessness With Your Usual Activities☐ Unexpected weight gain of more than 5 lbs in the last weeks or months	☐ Recent Cough
☐ Pain, pressure/discomfort in the chest	☐ Passed (ing) out-fainting
☐ Shortness of breath at rest, laying down	☐ worsening fatigue
☐ Any neck, jaw, left arm discomfort	☐ Swelling of the ankles
☐ Pain or cramps in leg(s) with walking	☐ Dizzy spells
☐ A stroke or temporary stroke	☐ Heart murmur
☐ Spells of rapid irregular heartbeat	☐ Heart attack
Urination at night	☐ Rheumatic fever
Abnormal EKG	□ Varicose veins
☐ Have you ever been hospitalized for your heart, or what (☐ Any other cardiac diagnosis?	hey thought was your heart?
☐ Any tests done for your heart? What tests?	
_ Any icolo uune lui yuui meaiti vinat icolo:	
When where they done?	
After any problems you wish to address at this visit?	
	-
Cholestirol test, monagement	
<u> </u>	
	. <u></u>
	<u></u>
	· · · · · · · · · · · · · · · · · · ·
	<u> </u>
	<u> </u>
· · · · · · · · · · · · · · · · · · ·	
call galv	12/12/09
	To 4
Patient name (sign)	Date
	T) - 4 -
Witness	Date

### **INSURANCE INFORMATION**

Please provide us with your medical insurance information:	
PRIMARY INSURANCE POLICY:	
Company: SVN Mcrosyskons, Inc. Phone:	
Policy#: 67 x 290 AS 1981 Group: 17400 M106	
Name and SS# of Insured: 6 FAR II AD ABLOI S	5-577861
SECONDARY INSURANCE POLICY:	
Company:Phone:	
Policy #:Group:	
Name and SS# of Insured:	<u> </u>
OTHER INSURANCE:	
company:Phone:	······································
Policy #: Group:	
Name and SS# of Insured:	
ASSIGNMENT BENEFITS	
I HEREBY ASSIGN TO MICHAEL RICHMAN M.D., MY RIGHT TO AND INTER HEALTH CARE AND /OR SURGICAL BENEFITS, OTHERWISE PAYABLE TO MAND/OR SURGICAL TREATMENT RENDERED BY ANY OF THE ASSIGNEES. INSURANCE COMPANY TO MAKE PAYMENTS DDIECTLY TO THE ASSIGNE BLVD # 145A LOS ANGELES, CA 90025.  IN UNDERSTAND THAT I AM RESPONSIBLE FOR ANY CHARGES NOT PAID COMPANY(DZS), UNLESS SUCH CHARGES ARE LIMITED BY EXISTING CONBETWEEN THE ASSIGNEE AN MY MEDICAL CARRIER, AND THAT FINANCI ADDED TO ANY OUTSTANDING BALANCE, STARTING THIRTY DAYS FROM SUBMITTED TO MY INSURANCE COMPANY, OR FROM THE DATE OF MY FICHARGES ARE NOT COVERED BY MY INSURANCE COMPANY, I AUTHORIZ LISTED ABOVE TO RELEASE TO MY INSURANCE COMPANY/OR ITS REPRE AGENTS, ANY MEDICAL INFORMATION RELATIVE TO THE SERVICES RENACKNOWLEDGE THAT A PHOTOCOPY OR FAX OF THIS ORIGINAL IS AS V.ORIGINAL.	ME, FOR MEDICAL I HEREBY DIRECT MY E AT 1950 SAWTELLE BY MY INSURANCE ITRACT AGREEMENTS E CHARGES WDLL BE I THE DATE A BILL IS IRST STATEMENT, IF LE THE PHYSICIAN ISENTATIVES OR IDERED TO ME. I
full And	12//2/05

Your signature here

Today's date

## PRIVACY OF MEDICAL RECORDS

Our physicians and staff are fully and acutely aware of the potentially sensitive nature of the information contained in your medical record. Therefore, we ask that you provide us below with a list of those individuals or parties whom you intend to have access to such information in your medical records, and those whom you do not. Unless you request otherwise, it is our policy to share such information with the following individuals or parties:

- 1. Your next of kin, usually identified as the emergency contact and/or the person(s) who accompanies you during your office visit(s), spouse, child(ren), and/or parent(s);
- 2. Your medical insurance carrier and its agents;
- 3. Your referring physician and his/her staff;
- 4. The physicians and professionals to whom we make referrals, including the pathologist, radiologist, and anesthesiologist, and their staff.

We CANNOT bill your insurance company and/or collect any money from them on your behalf unless we have your permission to disclose such information to them. Also, the quality of your medical care might be compromised if our physicians do not have your permission to consider your case fully and frankly with other physicians and professionals who are involved in your medical care.

Please acknowledge below that you permit the foregoing individuals or parties to have access to the information contained in your medical records by signing below, and list additional individuals or parties that you permit access to such information.

THE FOLLOWING IS A LIST OF ADDITIONAL INDIVIDUALS OR PARTIES WHO HAVE MY PERMISSION TO ACCESS THE INFORMATION CONTAINED IN MY MEDICAL RECORD (IF THERE ARE NONE, WRITE IN "NONE"):

Your signature (required):  Please acknowledge beloaccess to the information contain	ow any individua	ls or parties that yo	
THE FOLLOWING IS A MY PERMISSION TO ACCESS RECORD (IF THERE ARE NO!	THE INFORMA	TION CONTAINE	ES WHO DO NOT HAVE D IN MY MEDICAL
Your signature (required): _	-		Date:

# The Center for Cholesterol Management

## PATIENT CONSENT FOR USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION (PHI)

With my consent, The Center for Cholesterol Management may use and disclose protected health information (PHI) about me to carry out treatment, payment, and healthcare operations (TPO). Please refer to The Center for Cholesterol Management's Notice of Privacy Practices (NOPP) for a more complete description of such uses and disclosures.

I have the right to review the Notice of Privacy Practices (NOPP) prior to signing this consent. The Center for Cholesterol Management reserves the right to revise its Notice of Privacy Practices (NOPP) at anytime. A revised NOPP may be obtained by forwarding a written request to The Center for Cholesterol Management at the address above.

With my consent, The Center for Cholesterol Management may call my home, office, and/or other locations and leave a message on voicemail, answering machine and/or directly reference me and/or any items that assist The Center for Cholesterol Management in carrying out TPO, such as appointment reminders, insurance items, lab reports, hospital reports, etc.. I agree that any such call or message pertaining to my clinical care, including laboratory results may reference me personally by name.

With my consent The Center for Cholesterol Management may mail to my home and/or other locations, items that assist The Center for Cholesterol Management to carry out TPO, such as appointment reminder cards, practice marketing brochures, patient statements, etc., as long as they are marked personal and/or confidential.

With my consent, The Center for Cholesterol Management may e-mail to my home and/or other locations as per the patient data sheet. I have the right to request that The Center for Cholesterol Management restrict how it uses or discloses my PHI to carry out TPO. However, The Center for Cholesterol Management is not required to agree to my requested restrictions, but if it does, it is bound by this agreement.

By signing this form, I am consenting to the aforementioned uses as well as The Center for Cholesterol Management's use and disclosure of my PHI to carry out TPO. I have received a copy of The Center for Cholesterol Management's Privacy Practices Policy (NOPP). I may revoke my consent in writing except to the extent that The Center for Cholesterol Management has already made disclosures in reliance upon my prior consent.

If I do not sign this consent, he Center for Cholesterol Management may decline to Signature of patient or legal guardian: X

Date: | 2/12/09

Patient's Name: CAMMAN ARSEN

Witness:



#### **BILLING POLICY**

We would like to prevent any misunderstanding about our billing financial policies. Please let the office administration know of you would like to discuss any of the following policies in more detail.

If you belong to an HMO, or any other restricted insurance plan, you MUST let us know before you are treated. Some of these plans limit your choice of doctor or hospital, and some exclude particular medical conditions. If you need surgery, we will try to select the hospital and doctors from your plan, although this might not always be possible or practical, particularly with the pathologist and the radiologist. Please provide our business office with all of your insurance information before you are treated, and we will help you fulfill the terms of your policy so that you can obtain maximum and timely reimbursement.

We will send you monthly statements until your insurance company has paid, regardless of our provider status. This allows you to verify that your insurance company was billed correctly, and to see how long they take to pay. If you have more than one insurance policy and the benefits are not coordinated, each company will determine benefits separately. In this situation, it might happen that we have different agreements with different companies. We will then collect benefits from each company and reimburse you any amount above billed charges.

Starting January 2001, you will also need to complete a separate form, "Privacy of Medical Records," so that we have a clear understanding of those individuals and parties whom you intend to have access to information contained in your medical record, and those whom you do not.

We accept Visa, MasterCard, and Diner's. There is a \$25 charge for all checks returned by the bank. If you would like us to bill your insurance company on your behalf, please complete the Assignment of Benefits sections below. Please sign below once you have had a chance to review our billing policies.

I AUTHORIZE MICHAEL RICHMAN M.D., AND STAFF TO PROVIDE ME WITH REASONABLE AND PROPER MEDICAL CARE.
I UNDERSTAND THAT I WILL HAVE AN OPPORTUNITY TO ASK QUESTIONS AND TO HAVE MY QUESTIONS ANSWERED, BEFORE I DECIDE TO PROCEED.

Your signature (required): KMW MM Date: 12/12/091

namana



CRACLE

Health Plan (80840) 911-87726-04

Member ID: 855269724

Group Number:

4450

Member:

FARMAD AABEDI

ORACLE

MEDIUM CHOICE PLUS PLAN

Dependents

SHAHRZAD AABEDI

Payer ID 87726

medco

Rx Bin: Rx Grp:

n: 610014 p: UHEALTH

Copay: Office Visit \$20 SPECOV \$30 UrgCare \$25 RX: Retail \$5 Gen/\$20 Br/\$40 Non-Pref

Mail Order \$10 Gen/\$40 Br/\$80 Non-Pref

UnitedHealthcare Choice Plus

0501

Administered by Unitedificate Insurance Company

Printed: 02/15/10

This card does not guarantee coverage. To verify benefits, view claims, or find a provider, visit the websites or call.

For Members: www.myuhc.com 866-672-25

866-672-2511

For Providers: www.unitedland.meansenline.com 877-842-3210 Medical Claims: PO 80X 30305, Salt Lake City, UT 84130-0355

Pharmacy Claims: PO BOX 14711, LEXINGTON KY 40512 For Pharmacists: 800-922-1557

For eligibility, coverage and claims information, please contact: A Preferred Provider Organization **Health Net PPO** 

Health Net Commercial Claims P.O. Box 14702 Lexington, KY 40512 For electronic claim submission infomation, please call 1-800-977-3568

Customer Contact Center: 1-800-839-2172 Provider Inquiries: 1-800-641-7761

Website:

Group Name

For denial questions will Health Net Dental at 1-866-249-2382. For vision questions will Health Net Vision at 1-866-392-6058.

www.healthnet.com

2001 # 11377

Health Net

PPC FAN INDIVIDUAL AND

ID Card Issue Date 01-01-2014

Group if 977GBW

Printary Insured 6 R06615960

Enredice 9 MMI

Type of Product
PPO WITH
PHARMACY
DENTAL WITH
VISION

FARHAD AABEDI

Stary Insured Name
FARHAD AABED!

ENROLLEES TRAVELING OUTSIDE THE STATE OF CALIFORNIA, CAN RECEIVE IN-NETWORK LEVEL OF BENEFITS BY ACCESSING THE FIRST HEALTH PPO NETWORK. TO LOCATE A PARTICIPATING FIRST HEALTH PROVIDER, PLEASE CALL 1-800-839-2172 OR WWW.HEALTHNET.COM

.

n,z



TO LOCATE A HEALTH NET PHARMACY, PLEASE CALL THE CUSTOMER CONTACT CENTER
Rx BIN#004336 Rx PCN HNET Rx Caremark
Pharmacist: For assistance, call Pharmacy Help Line at 1-800-800-0180



THE RESERVE OF THE PERSON NAMED IN COLUMN TWO IS NOT THE OWNER.

PPO INDIVIDUAL AND FAMILY

This is your Health Net PPO identification eard. Carry it with you at all times neceive services. See your braich care provider when you or your eligible dependents. When sabmirting inquiries about your coverage, shways include your group and printary insured ID number from the face of this card.

PRE-CERTIFICATION


You the enrolled are responsible for obtaining certification for certain services. Please check your plan certification, please call 1-803-977-7282

For pre-certification, please call 1-803-977-7282

To reach a registered number 34/7 call 1-803-973-5697 or TTY/TDD:

MultiPlan

For non-network negotiation services only



ichael F. Richman, M.D., F.A.C.S. lothoracic, General and Vein Surgery LIC# G74625 • DEA# BR3315567 1950 Sawtelle Boulevard, # 150 Los Angeles, CA 90025 (310)481-3939 • Fax (310)481-3949 ☐ Female ∠\_ D.O.B. Name . □ Male Address Phone, Quantity: 1-24 17/25-49 □ 50-74 □75-100 □101-150 □151 and over Refilis — ☐ □ NR □ 1 □ 2 □ 3 □ 4 🕽 6 冠 🗘 o not substitute 🖰 Initjal 🗀 Quantity: 1-24 2) Refills — → ONR □1□2□3 □4 **2**€ Initial Do not substitute Quantity: 1-24 25-49 50-74 D75-100 □101-150 □151 and over - Refills -\_ONR O10203 04 05 □ Do not substitute ligitial ... Prescription is VOID if the number of gruge prescribed is not rated. <u>Date</u> **≸**223RP